Turn Therapeutics appoints former FDA Commissioner Dr. Stephen Hahn as clinical and regulatory lead

Turn Therapeutics Inc.

Dr. Stephen M. Hahn, former FDA Commissioner, appointed to oversee clinical and regulatory strategy for GX-03.
GX-03 is a topical therapy in Phase 2 trial for moderate-to-severe atopic dermatitis (eczema).
Hahn cited personal family experience with atopic dermatitis as motivation for his role.
CEO Bradley Burnam highlighted Hahn's scientific rigor, regulatory expertise, and patient focus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.